Oncology
Biosimilars/Oncology

Afatinib
Form: Tablet
THERAPEUTIC AREA: Oncology

Enzalutamide
Form: Capsule
THERAPEUTIC AREA: Oncology

Eribulin
Form: IV Solution
THERAPEUTIC AREA: Oncology

Gefitinib
Form: Tablet
THERAPEUTIC AREA: Oncology

Ibrutinib
Form: Capsule
THERAPEUTIC AREA: Oncology

Lenalidomide
Form: Capsule
THERAPEUTIC AREA: Oncology

Lenvatinib
Form: Capsule
THERAPEUTIC AREA: Oncology

Nilotinib
Form: Capsule
THERAPEUTIC AREA: Oncology

Palbociclib
Form: Tablet
THERAPEUTIC AREA: Oncology

Pomalidomide
Form: Capsule
THERAPEUTIC AREA: Oncology

Ruxolitinib
Form: Tablet
THERAPEUTIC AREA: Oncology

Sunitinib
Form: Capsule
THERAPEUTIC AREA: Oncology

Temozolomide
Form: Capsule
THERAPEUTIC AREA: Oncology
GlobalOne Healthcare Holding
In addition to licensing, the organization is committed to expanding market presence and contract manufacturing for operating companies across the Middle East, Africa, and beyond. This can facilitate the distribution of important healthcare products to regions where they may not be readily available, improving access to care and promoting better health outcomes. Through its commercial partners, the organization can also leverage local knowledge and expertise to navigate the complexities of these markets and ensure the successful introduction of new products.
Finally, the organization recognizes the importance of investing in late-stage biotech and health/medtech startups to expand its healthcare portfolio globally. By supporting the development of promising new products and technologies, the organization can contribute to the advancement of healthcare and improve outcomes for patients around the world. These investments can also generate returns for the organization and its partners, helping to fund future innovation and growth. Overall, the organization’s mandate reflects a commitment to driving innovation, improving access to care, and promoting better health outcomes for all.